Serum calcitonin is independently related with endothelial dysfunction in patients with chronic kidney disease (CKD), data suggest.
Mehmet Kanbay, MD, of Kayseri Training and Research Hospital in Kayseri, Turkey, and collaborators studied 84 non-diabetic CKD patients (41 men) with a mean age of 13.3 years. Patients with serum calcitonin levels above the median had significant lower flow-mediated dilatation (FMD) than those with levels below the median (6.87% vs. 7.23%), the researchers reported online ahead of print in International Urology and Nephrology.
In multivariate regression analysis, serum calcitonin, fetuin-A, high-sensitive C-reactive protein, and hemoglobin were independently associated with FMD.
The independent association of serum calcitonin with endothelial dysfunction deserves additional experimental and clinical exploration “to elucidate whether calcitonin is an innocent bystander or has a pathophysiologic relationship” with endothelial dysfunction in CKD patients, the authors concluded.